Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EBIT (2021 - 2025)

Historic EBIT for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $1.6 million.

  • Verrica Pharmaceuticals' EBIT rose 10785.84% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.4 million, marking a year-over-year increase of 7887.44%. This contributed to the annual value of -$65.9 million for FY2024, which is 24.33% down from last year.
  • Per Verrica Pharmaceuticals' latest filing, its EBIT stood at $1.6 million for Q3 2025, which was up 10785.84% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Verrica Pharmaceuticals' EBIT peaked at $1.6 million during Q3 2025, and registered a low of -$23.9 million during Q3 2023.
  • Moreover, its 5-year median value for EBIT was -$9.1 million (2022), whereas its average is -$9.9 million.
  • Over the last 5 years, Verrica Pharmaceuticals' EBIT had its largest YoY gain of 11230.46% in 2022, and its largest YoY loss of 1245000.0% in 2022.
  • Quarter analysis of 5 years shows Verrica Pharmaceuticals' EBIT stood at -$8.5 million in 2021, then increased by 26.67% to -$6.2 million in 2022, then plummeted by 272.5% to -$23.1 million in 2023, then surged by 50.68% to -$11.4 million in 2024, then skyrocketed by 114.26% to $1.6 million in 2025.
  • Its EBIT stands at $1.6 million for Q3 2025, versus $1.5 million for Q2 2025 and -$8.1 million for Q1 2025.